Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PHARMAC and the statin debacle.

Chris Ellis1, Harvey White

  • 1Greenlane Cardiovascular Service, Auckland City Hospital, Auckland. chrise@adhb.govt.nz

The New Zealand Medical Journal
|June 30, 2006
PubMed
Summary

Statins effectively reduce cardiovascular events by lowering LDL cholesterol. However, PHARMAC

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Demographic Refinement and Atrial Fibrillation Type in Stroke Risk Stratification Beyond CHA2DS2 VASc.

Cerebrovascular diseases extra·2026
Same author

An Asia Pacific Perspective on the 2026 AHA/ACC Guideline for Acute Pulmonary Embolism.

Journal of the American College of Cardiology·2026
Same author

Ethnic differences in population-level intracerebral haemorrhage incidence in Aotearoa New Zealand: findings from three Auckland Regional Community Stroke cohorts.

The New Zealand medical journal·2026
Same author

Correction: Comparison of frailty instruments for predicting mortality and prolon ged hospitalization in acute coronary syndrome patients.

PloS one·2025
Same author

Association Between Electrocardiographic Changes and Myocardial Injury or Death After Cardiac Surgery.

The Canadian journal of cardiology·2025
Same author

Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy.

Arteriosclerosis, thrombosis, and vascular biology·2025

Area of Science:

  • Cardiovascular Medicine
  • Pharmacoeconomics

Background:

  • Statins are proven lipid-modifying drugs that significantly reduce cardiovascular events like heart attacks and strokes.
  • Clinical trials demonstrate a 1% reduction in major coronary heart disease events for every 1% decrease in LDL cholesterol.
  • Optimal management guidelines emphasize low LDL cholesterol levels (1.6 mmol/L) for high-risk patients.

Purpose of the Study:

  • To review PHARMAC's actions regarding statin availability in New Zealand.
  • To analyze how PHARMAC's methods impact the timely delivery of modern medicines.

Main Methods:

  • Review of historical data and actions by PHARMAC concerning statin procurement and availability.
  • Analysis of the impact of PHARMAC's drug management strategies on patient access to statins.

Main Results:

  • PHARMAC's actions have impeded the optimal management of New Zealand patients requiring statins.
  • The focus on low drug prices by PHARMAC has hindered timely access to essential cardiovascular medications.

Conclusions:

  • PHARMAC's approach prioritizes cost reduction over timely patient access to effective statin therapy.
  • A review of PHARMAC's methods highlights systemic issues in drug delivery to New Zealand patients.

Related Experiment Videos